
Opinion|Videos|May 14, 2024
Treatment Options for mHSPC
In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.
Advertisement
Episodes in this series

Advertisement
Related to this article

During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
ETHAN Trial: Rethinking Endocrine Therapy for Men's Breast Cancer
3
Contrasting Myeloma Therapies for Late Relapse in Patient Declining CAR T
4
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
5

